139 results on '"Pike J"'
Search Results
2. PCR3 EQ-5D Utilities for Patients With Nonalcoholic Steatohepatitis (NASH): A Comparison of Historical Utilities to a Recent Real-World Multi-Country Patient Survey
3. PNS66 Stated Importance Versus Actual Impact: An Evaluation of HTA Practices to Incorporate Patient Perspectives in Value Assessments
4. PND93 First LINE Treatment with Natalizumab Reduces Healthcare Resource Use and Work Productivity and Activity Impairment in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Compared to Natalizumab Delayed Use
5. PMH6 Association of Atypical Treatment Switches with Outcomes in Patients with Schizophrenia
6. PCN310 Real World Burden and Impact of Brain Metastases on Quality of Life and Healthcare Resource Utilization Among Metastatic Breast Cancer Patients
7. PCN323 Health Status/Utilities in Adult Patients with Germline BRCA1/2 Mutated (GBRCA1/2MUT) HER2− Advanced Breast Cancer (ABC) Treated with POLY(ADP-RIBOSE) Polymerase Inhibitors (PARPI) Versus Chemotherapy in a Real World (RW) Setting
8. PR1 DEVELOPMENT OF A CROSS-WALK OF THE ASSESSMENT OF SPONDYLOARTHRITIS INTERNATIONAL SOCIETY HEALTH INDEX (ASAS HI) AND ANKYLOSING SPONDYLITIS QUALITY OF LIFE (ASQOL) SCORES USING DATA FROM PATIENTS WITH ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
9. CN1 HEALTH RELATED QUALITY OF LIFE AMONG PATIENTS WITH EARLY BREAST CANCER: A MULTINATIONAL STUDY
10. PND86 THE BURDEN OF INCREMENTAL “OFF” HOURS ON CAREGIVERS OF PATIENTS WITH PARKINSON’S DISEASE: A NEUROLOGIST⁄PATIENT⁄CAREGIVER REAL-WORLD ASSESSMENT IN THE US
11. PMU19 FIRST LINE TREATMENT WITH NATALIZUMAB REDUCES HEALTHCARE RESOURCE USE AND IMPAIRMENT OF WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) PATIENTS COMPARED TO NATALIZUMAB DELAYED USE
12. PRO9 RELATIONSHIP BETWEEN PROGRESSIVE SUPRANUCLEAR PALSY AND HEALTHCARE RESOURCE UTILIZATION
13. PND22 THE BURDEN OF NON-MOTOR SYMPTOMS ON HEALTHCARE RESOURCE UTILISATION AMONG PATIENTS WITH PARKINSON'S DISEASE: A NEUROLOGIST/PATIENT REAL-WORLD ASSESSMENT IN THE US
14. PMH62 AN ASSESSMENT OF THE HUMANISTIC IMPACT OF SCHIZOPHRENIA IN RELATION TO CAREGIVER AND PRODUCTIVITY BURDEN
15. PMH65 ASSESSMENT OF OUTCOMES AND SYMPTOM SEVERITY IN SCHIZOPHRENIA PATIENTS ACCORDING TO PHYSICIAN PERCEPTION OF ILLNESS
16. PMH63 A REAL WORLD ASSESSMENT OF OUTCOMES IN SCHIZOPHRENIA PATIENTS ACCORDING TO TREATMENT RESPONSE
17. PIN5 REAL WORLD EXPERIENCE WITH DOLUTEGRAVIR-BASED TWO-DRUG REGIMENS
18. PMH54 ASSESSMENT OF OUTCOMES IN PARTIALLY VERSUS FULLY COMPLIANT SCHIZOPHRENIA PATIENTS
19. PND117 - PHYSICIAN REPORTED ADHERENCE IN MS PATIENTS TREATED WITH INJECTABLE PLATFORM THERAPIES VERSUS DELAYED-RELEASE DIMETHYL FUMARATE: FINDINGS FROM A REAL-WORLD CROSS-SECTIONAL STUDY
20. ND2 - FUNCTIONAL LOSS ACROSS STAGES OF ALZHEIMER’S
21. PND45 - CAREGIVER NEED ACROSS STAGES OF ALZHEIMER’S
22. PND8 - PEGINTERFERON BETA-1A IS ASSOCIATED WITH REDUCED RELAPSE RATES AND HOSPITALISATIONS DUE TO RELAPSE COMPARED WITH OTHER FIRST-LINE INJECTABLE THERAPIES FOR MULTIPLE SCLEROSIS: FINDINGS FROM A REAL-WORLD CROSS-SECTIONAL STUDY
23. PND83 - HEALTH RESOURCE UTILIZATION ACROSS STAGES OF ALZHEIMER’S
24. PND79 - REDUCED HEALTHCARE RESOURCE UTILISATION FOR PATIENTS TREATED WITH DELAYED RELEASE DIMETHYL FUMARATE VS INJECTABLE THERAPIES: FINDINGS FROM A REAL-WORLD CROSS-SECTIONAL STUDY OF MS PATIENTS
25. PND155 - REDUCED RELAPSE RATES AND IMPROVED QUALITY OF LIFE FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) PATIENTS TREATED WITH NATALIZUMAB VS INJECTABLE THERAPIES
26. Relapsing-Remitting Multiple Sclerosis Patients On Dimethyl Fumarate Reported Less Physical And Psychological Disease Impact In The Real World Compared With Patients On Platform Therapies
27. Predicting EQ-5D Utility Index Scores for Gastric Cancer Patients in Japan: A Preliminary Model
28. Relapse Rates and Symptom Management Among Patients Receiving Natalizumab and other Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis
29. A Regional Analysis of Relapsing Remitting MS (RRMS) Patients Treated with Natalizumab Suggests a Need to Diagnose and Treat Early in Latin Americans
30. Cost And Resource Utilization Among Multiple Sclerosis Patients With Increasing Disability In Latin America
31. Assessment of Patient Preferences in the Treatment of Relapsing-Remitting Multiple Sclerosis in Public and Private Systems in Latin America
32. The Impact Of Increasing Disability On Employment And Caregiver Burden Among Multiple Sclerosis Patients In Brazil
33. An Evaluation of Disability Progression and Quality of Life in Multiple Sclerosis Patients in Brazil and Mexico
34. Factors Associated With A History Of Failure And Switching Migraine Prophylaxis Treatment: An Analysis Of Clinical Practice Data From The United States, Germany, France, And Japan
35. Treatment with interferon beta-1a in brazil is associated with fewer hospitalizations due to relapse, better adherence and a better response compared to other platform therapies
36. Characterizing Patient-Reported Health-Related Quality-Of-Life Measures Among Users And Non-Users Of Migraine Prophylaxis Treatment: An Analysis Of Clinical Practice Data From The United States, Germany, France, And Japan
37. The Impact of Increasing Multiple Sclerosis (Ms) Severity Level on Employment and Caregiver Burden
38. Differences In Work Productivity Activity Imparment In Rrms Patients Initiated on Oral Dmf or Platform Therapies In Europe and Us
39. Relapsing Remitting Multiple Sclerosis Patients Initiated on Oral Dmf Report A Better Quality of Life Compared to Patients on Platform Therapies As Measured By Eq-5d
40. Differences In Disease Specific Hrqol In Rrms Patients Initiated on Oral Dmf Or Platform Therapies In Europe And Us
41. Impact of walking impairment on Healthcare resource utilisation in multiple sclerosis Patients
42. The evaluation of work productivity in relapsing-remitting (Rrms) and secondary progressive multiple sclerosis (Spms) Patients in Europe
43. PND6 - Relapsing-Remitting Multiple Sclerosis Patients On Dimethyl Fumarate Reported Less Physical And Psychological Disease Impact In The Real World Compared With Patients On Platform Therapies
44. PCN196 - Predicting EQ-5D Utility Index Scores for Gastric Cancer Patients in Japan: A Preliminary Model
45. Establishing the Relationship of Inhaler Satisfaction, Adherence, Smoking History and Allergic Rhinitis With Patient Outcomes: Real World Observations in US Adult Asthma Patients
46. Self-Reported Health Related Quality Of Life Of Hepatitis C Virus (Hcv) Genotype 1 Patients With And Without Comorbid Conditions
47. PDB69 - Patient-Reported Need vs. Concern Around Injectable Therapy and Impact on Adherence: A Real-World Survey of 5EU/US T2DM Patients
48. PND67 - A Regional Analysis of Relapsing Remitting MS (RRMS) Patients Treated with Natalizumab Suggests a Need to Diagnose and Treat Early in Latin Americans
49. PND54 - The Impact Of Increasing Disability On Employment And Caregiver Burden Among Multiple Sclerosis Patients In Brazil
50. PND58 - Assessment of Patient Preferences in the Treatment of Relapsing-Remitting Multiple Sclerosis in Public and Private Systems in Latin America
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.